Financial Performance - For the six months ended December 31, 2024, revenue was approximately HKD 39,500,000, a decrease of about 20.5% compared to HKD 49,700,000 for the same period in 2023[3] - Profit before tax for the same period was approximately HKD 12,900,000, down approximately 38.6% from HKD 21,000,000 in the previous year[3] - The profit attributable to equity holders of the company was approximately HKD 10,100,000, representing a decrease of about 40.9% from HKD 17,100,000 for the same period in 2023[3] - Operating profit for the period was HKD 13,821,000, down from HKD 21,091,000 in the previous year[4] - Total comprehensive income for the period was HKD 14,026,000, compared to HKD 15,836,000 for the same period in 2023[6] - Basic earnings per share for the six months ended December 31, 2024, were HKD 2.51, compared to HKD 4.28 for the same period in 2023, reflecting a decrease of approximately 41%[32] - The group reported a profit attributable to equity holders of HKD 10,108,000 for the six months ended December 31, 2024, down from HKD 17,123,000 in the previous year, a decline of about 41%[32] - The profit for the period is approximately HKD 10,100,000, a decrease of about 40.9% from approximately HKD 17,100,000 for the period ending December 31, 2023[58] Dividends - The company declared an interim dividend of HKD 10,061,500 (HKD 0.025 per share) for the six months ended December 31, 2024[3] - The interim dividend for the six months ending December 31, 2024, is set at HKD 2.5 per share, compared to HKD 5.0 per share for the same period last year[35] - The company declared a final dividend of HKD 15,000,000 (HKD 3.75 per share) for the year ending June 30, 2023[35] - The company plans to distribute an interim dividend of HKD 0.025 per share, totaling HKD 10,061,500, to shareholders on March 21, 2025[87] - The company will suspend the transfer of shares from March 12 to March 14, 2025, to facilitate the interim dividend distribution[88] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 313,699,000, a slight decrease from HKD 318,062,000 as of June 30, 2024[8] - The total equity attributable to equity holders of the company was HKD 222,734,000, up from HKD 218,326,000 as of June 30, 2024[8] - Total liabilities decreased from HKD 99,736 thousand to HKD 90,965 thousand, a reduction of approximately 8.7%[10] - Current liabilities decreased from HKD 99,702 thousand to HKD 90,696 thousand, reflecting a decline of about 9.9%[10] - The company's total assets decreased slightly from HKD 318,062 thousand to HKD 313,699 thousand, a decline of approximately 1.1%[10] - Trade receivables as of December 31, 2024, amounted to HKD 31,809,000, down from HKD 38,907,000 as of June 30, 2024[37] - The net current assets decreased from approximately HKD 28,300,000 as of June 30, 2024 to approximately HKD 26,600,000 as of December 31, 2024[63] - Total outstanding borrowings amounted to HKD 62,000,000, classified as short-term loans[65] Cash Flow - Cash generated from operating activities was HKD 17,610 thousand, compared to a cash usage of HKD 501 thousand in the previous period[13] - Net cash used in investing activities was HKD 5,512 thousand, an increase from HKD 1,835 thousand in the prior period[13] - Net cash used in financing activities was HKD 13,331 thousand, down from HKD 16,212 thousand year-over-year[13] - Cash and cash equivalents at the end of the period totaled HKD 79,868 thousand, compared to HKD 74,723 thousand at the end of the previous period[13] - As of December 31, 2024, the group maintained cash and cash equivalents of approximately HKD 79,900,000, a decrease from HKD 81,100,000 as of June 30, 2024[63] - Cash and bank balances were reported at HKD 79,615,000 as of December 31, 2024, compared to HKD 80,936,000 as of June 30, 2024[39] Employee Expenses - Employee benefit expenses increased to HKD 14,329,000 from HKD 12,212,000 in the previous year[4] - The group’s employee benefit expenses, including director remuneration, increased to HKD 14,329,000 in the six months ended December 31, 2024, from HKD 12,212,000 in the same period of 2023, an increase of about 17%[28] - Employee costs for the period totaled approximately HKD 14,300,000, compared to HKD 12,200,000 for the six months ended December 31, 2023[75] Strategic Focus - The group is focused on maintaining financial stability amid geopolitical tensions and inflation pressures while pursuing strategic partnerships and service expansion opportunities[49] - The company aims to reallocate its investment portfolio in response to current market conditions and future developments[46] - The group had no major future investment or capital asset plans as of December 31, 2024[73] Corporate Governance - The company is committed to maintaining high standards of corporate governance and transparency to protect the interests of shareholders[82] - The board will continue to review the effectiveness of the corporate governance structure, including the separation of the roles of Chairman and CEO[85] - The audit committee, consisting of three independent non-executive directors, has reviewed the interim results and confirmed compliance with applicable accounting policies and standards[86] - The company has adopted the standard code of conduct for securities trading as per the listing rules, ensuring compliance by directors during the period[81] Employment and Personnel - The group employed a total of 75 employees as of December 31, 2024, an increase from 55 employees as of June 30, 2024[75] - The group has approximately 30,000 registered healthcare personnel as of December 31, 2024[47] Other Income and Expenses - The group incurred income tax expenses of HKD 2,798,000 for the six months ended December 31, 2024, compared to HKD 3,893,000 in the same period of 2023, a decrease of approximately 28%[30] - The group’s interest income from bank deposits was HKD (808,000) for the six months ended December 31, 2024, slightly improved from HKD (856,000) in the previous year[28] - Other income for the period is approximately HKD 700,000, an increase from HKD 400,000 for the period ending December 31, 2023[54] Market Conditions - The group had no significant foreign currency risk as most transactions were conducted in HKD[64] - The group expects no significant impact from newly issued accounting standards on its current or future reporting periods[23]
百本医护(02293) - 2025 - 中期业绩